Mitochondrial Diabetes Treated With a Sodium-Glucose Co-Transporter 2 Inhibitor

Abstract

Recent animal studies have suggested that sodium-glucose co-transporter 2 (SGLT2) inhibitors have mitochondrial and cardiorenal protective effects. Herein we report the case of mitochondrial diabetes successfully treated with an SGLT2 inhibitor empagliflozin. Although the underlying mechanisms have still not been completely investigated, SGLT2 inhibitors may improve mitochondrial function, suppress oxidative stress and restore autophagy. SGLT2 inhibitors could be a treatment option for patients with mitochondrial diabetes.




J Endocrinol Metab. 2019;9(6):203-204
doi: https://doi.org/10.14740/jem627